Traws Pharma Inc.

NASDAQ: TRAW · Real-Time Price · USD
1.50
-0.12 (-7.41%)
At close: Aug 15, 2025, 12:39 PM

Traws Pharma Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
2.73B 227K 226K 226K 226K 226K 226K 226K 226K 226K 226K 226K 226K 226K 226K 227K 236K 235K
Cost of Revenue
4K 8K 12K 14K 17K 17K 16K 16K 14K 14K 14K 14K 11K 7K 4K n/a n/a n/a
Gross Profit
168K 221K 216K 214K 209K 209K 210K 210K 212K 212K 212K 212K 215K 219K 222K 227K 236K 235K
Operating Income
-1.39B -142.37M -142.37M -24.09M -20.65M -19.37M -20.3M -21.57M -22.12M -21.63M -19.63M -17.66M -16M -16.53M -16.5M -18.99M -21.27M -23.97M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-931.91M -140.05M -166.52M -140.78M -137.05M -18.16M -18.95M -20.18M -20.84M -20.62M -18.96M -17.31M -15.36M -15.57M -16.16M -18.82M -21.61M -24.78M
Net Income
-931.91M -140.05M -166.52M -140.78M -137.05M -18.16M -18.95M -20.18M -20.84M -20.62M -18.96M -17.31M -15.36M -15.57M -16.16M -18.83M -21.62M -24.78M
Selling & General & Admin
1.7B 11.69M 12.29M 10.9M 10.1M 10.34M 9.09M 9.03M 8.45M 8.37M 8.45M 8.5M 8.68M 9.39M 9.43M 9.13M 8.99M 8.74M
Research & Development
2.3B 13.44M 12.84M 13.41M 10.76M 9.26M 11.43M 12.77M 13.89M 13.47M 11.39M 9.36M 7.53M 7.35M 7.29M 10.08M 12.51M 15.46M
Other Expenses
25,136B 25,136B 25,136B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
25,140B 25,136B 25,136B 24.31M 20.86M 19.59M 20.52M 21.79M 22.34M 21.85M 19.84M 17.87M 16.22M 16.74M 16.71M 19.21M 21.5M 24.2M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
19.19M 25.13M 25.14M 24.32M 20.87M 19.6M 20.52M 21.8M 22.35M 21.86M 19.85M 17.88M 16.23M 16.76M 16.72M 19.21M 21.51M 24.2M
Income Tax Expense
n/a n/a n/a n/a n/a n/a -38.58K -38.58K -62.66K -62.66K -24.08K -24.08K 1.00 1.00 n/a 4K 4K 4K
Shares Outstanding (Basic)
58.21M 25.31M 25.31M 25.31M 25.31M 21.04M 21M 21M 20.98M 20.96M 20.93M 20.92M 20.9M 20.9M 20.9M 15.98M 15.78M 14.62M
Shares Outstanding (Diluted)
58.21M 25.31M 25.31M 25.31M 25.31M 21.04M 21M 21M 20.98M 20.96M 20.93M 20.92M 20.9M 20.9M 20.9M 15.98M 15.78M 14.62M
EPS (Basic)
0.59 -4.17 -6.58 -5.64 -5.54 -0.87 -0.91 -0.97 -1 -0.99 -0.91 -0.83 -0.79 -0.87 -0.99 -1.35 -1.65 -2.03
EPS (Diluted)
0.51 -4.25 -6.58 -5.64 -5.54 -0.87 -0.91 -0.97 -1 -0.99 -0.91 -0.83 -0.79 -0.87 -0.99 -1.35 -1.65 -2.03
EBITDA
-1.27B -24.89M -24.9M -24.08M -20.63M -19.36M -20.28M -21.55M -22.11M -21.62M -19.61M -17.64M -15.99M -16.52M -16.48M -18.97M -21.26M -23.95M
EBIT
-19.02M -24.9M -24.91M -24.09M -20.65M -19.37M -20.3M -21.57M -22.12M -21.63M -19.63M -17.66M -16M -16.53M -16.5M -18.99M -21.27M -23.97M
Depreciation & Amortization
5K 9K 12K 14K 17K 17K 16K 16K 14K 14K 14K 14K 14K 14K 14K 14K 15K 13K